GlobeNewswire
-
Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
16/11/2026 -
IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
16/11/2026 -
FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
16/11/2026 -
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
17/11/2026 -
Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
17/11/2026 -
Ziphius, une société de biotechnologie de premier plan spécialisée dans l’ARN auto-amplificateur, annonce aujourd’hui la nomination de M. Antoon Loomans au sein de son conseil d’administration
17/11/2026 -
AGC Biologics Welcomes Multiple Cell Therapy Projects to New Yokohama Site
17/11/2026 -
NKGen Biotech Reports Long-Term Clinical Observations with Investigational Alzheimer’s Treatment Troculeucel at CTAD 2026
16/11/2026 -
Galimedix Therapeutics outlines development plans in Alzheimer's disease at CTAD 2026
16/11/2026 -
Exicure Announces Filing of Notification of Late Filing on Form 12b-25
16/11/2026 -
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
16/11/2026 -
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/11/2026 -
Stipple Bio Announces Multi-Target Multi-Modality Oncology Research Collaboration with Lilly
16/11/2026 -
Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization
16/11/2026 -
Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola
16/11/2026 -
Carlsmed to Participate in Upcoming Investor Conferences
16/11/2026 -
Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results
16/11/2026 -
Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement
16/11/2026 -
Windward Bio Announces Closing of $251.2 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16/11/2026
Pages